1182 A Case of Hypersomnolence in a Solid-Organ Transplant Recipient

Lana Mukharesh,Amee Revana
DOI: https://doi.org/10.1093/sleep/zsae067.01182
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Epstein-Barr virus (EBV) infects more than 90% of humans worldwide, with no evidence of active infection and persists for life. In pediatric renal transplant recipients, EBV primary infection or reactivation occur more frequently (63% and 44%, respectively). There is limited data to suggest duration of symptoms secondary to EBV and treatment options for pediatric hypersomnia secondary to EBV infection. Report of case(s) We describe a case of hypersomnia in a 7-year-old male with ADHD. He had received a renal transplant three years prior, secondary to renal dysplasia from a deceased donor who was EBV positive. He had a baseline polysomnogram (PSG) completed for symptoms of snoring, witnessed apneas and nocturnal enuresis, and was diagnosed with severe obstructive sleep apnea. He was started on CPAP and demonstrated excellent adherence to positive airway pressure (PAP). At age 9, he developed hypersomnolence, where he would sleep for 12-16 hours a day, fall asleep in school, during meals and vacation trips. The parents reported he was diagnosed with EBV a few months prior (EBV IgG and EBV nuclear antigen positive). Completed diagnostic work up included PAP device interrogation with adherence data, an actigraphy, a diagnostic PSG while on PAP and a multiple sleep latency test (MSLT). All the work up was reassuring, except for the MSLT where the patient had a sleep onset latency of 11 minutes and 3 out of 5 naps with sleep onset REM periods. Over the course of his evaluation, his pediatric daytime sleepiness scale ranged between 20-28 (>15 is significant). He was started on atomoxetine, with some reported improvement in hypersomnolence. Repeat PSG revealed primary snoring; therefore, PAP was discontinued. At age 15, his hypersomnolence had resolved, but conversely, exhibited difficulty initiating and maintaining sleep with higher doses of atomoxetine, therefore it was discontinued after 5 years of treatment. Conclusion In pediatric solid-organ transplant recipients with EBV infection, it is imperative to screen for excessive daytime sleepiness in order to facilitate therapies to improve overall quality of life, as well as recognize that the excessive daytime sleepiness may be a short-term symptom. Support (if any)
neurosciences,clinical neurology
What problem does this paper attempt to address?